Welcome to Neuronet
According to the European Commission, an estimated 165 million Europeans are living with a brain disorder. These include neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease and multiple sclerosis, which are tied to a gradual loss of brain cells.
A number of research projects launched by the Innovative Medicines Initiative, Europe's biggest public and private collaboration in life sciences, aim to better understand and develop treatments for these conditions. By establishing the Neuronet platform and connecting these projects, we hope to aid progress and expedite the delivery of novel treatments.
Neuronet aims to help scientists to identify gaps in research, to make findings more visible for society as a whole and create links between Innovative Medicines Initiative projects and other international research initiatives.
“Neurodegenerative diseases are an area of major unmet medical need and have been a priority for IMI since the very beginning. By bringing together IMI’s excellent projects in this important area, Neuronet will help the projects to collectively make progress and give new hope to the millions of people in Europe and beyond who are affected by these diseases.”
Dr Pierre Meulien
Executive Director, Innovative Medicines Initiative (IMI).
“Public-Private Partnerships such as IMI are powerful enablers of innovation in the healthcare sector. I see Neuronet as an ideal knowledge integrator, interaction facilitator and striver for sustainable outcomes in support of the various IMI Neurodegeneration projects and beyond. In the end, we all want to make sure these results benefit the wider research community and help us accelerate bringing solutions to patients faster than ever before."
Dr Lennert Steukers
Manager, Clinical Scientist,
Janssen Pharmaceutica NV, Neuronet Project Leader.
“Neuronet has been designed to take a different approach to a typical Coordination and Support Action: we want to effectively connect resources and needs of the different projects ‘just in time’, making sure that we serve the projects and not vice versa. This demands a dynamic structure that puts the projects at the steering wheel, with Neuronet focusing on being a key enabler and mediator across the whole IMI neurodegeneration portfolio.”
Mr Carlos Díaz
CEO, SYNAPSE Research Management Partners (SYNAPSE), Neuronet Project Coordinator.
“We are delighted to be partners in Neuronet. The partnership will support neurodegeneration research funded by the Innovative Medicines Initiative, with the aim that people with neurodegenerative diseases will receive innovative treatments without unnecessary delay.”
Dr Jacoline Bouvy
Senior Scientific Adviser, National Institute for Health and Care Excellence (NICE).
“Ensuring we are capturing and fully advancing the immense knowledge created in the numerous Neurodegeneration IMI projects is the key deliverable of Neuronet. This is critical if we are to make significant headway in the discovery of novel therapeutics for these devastating brain disorders.”
Dr Darrel Pemberton
Senior Director, Janssen Pharmaceutica NV, Former Neuronet Project Leader.
“Our mission at Parkinson’s UK is to deliver new and better treatments as quickly as possible. The Innovative Medicines Initiative is a major contributor to neurodegenerative research and we believe the Neuronet platform will play a key role in aiding progress towards new treatments for conditions such as Parkinson’s.”
Dr Jill Gallagher
Clinical Development and Regulatory Manager,